Article
Ovarian Cancer-Specific BRCA-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Dec 2021
Schouten Philip C, Richters Lisa, Vis Daniel J, Kommoss Stefan, van Dijk Ewald, Ernst Corinna, Kluin Roelof J C, Marmé Frederik, Lips Esther H, Schmidt Sandra, Scheerman Esther, Prieske Katharina, van Deurzen Carolien H M, Burges Alexander, Ewing-Graham Patricia C, Dietrich Dimo, Jager Agnes, de Gregorio Nikolaus, Hauke Jan, du Bois Andreas, Nederlof Petra M, Wessels Lodewyk F, Hahnen Eric, Harter Philipp, Linn Sabine C, Schmutzler Rita K
Abstract excerpt
PURPOSE: Previously, we developed breast cancer BRCA1-like and BRCA2-like copy-number profile shrunken centroid classifiers predictive for mutation status and response to therapy, targeting homologous recombination deficiency (HRD). Therefore, we investigated BRCA1- and BRCA2-like classification in ovarian cancer, aiming to acquire classifiers with similar properties as those in breast cancer.Experimental Design:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.